These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 23755891)

  • 21. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
    Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
    Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR.
    Wang YL; Overstreet AM; Chen MS; Wang J; Zhao HJ; Ho PC; Smith M; Wang SC
    Oncotarget; 2015 May; 6(13):11150-61. PubMed ID: 25883211
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
    Al-Ejeh F; Shi W; Miranda M; Simpson PT; Vargas AC; Song S; Wiegmans AP; Swarbrick A; Welm AL; Brown MP; Chenevix-Trench G; Lakhani SR; Khanna KK
    J Nucl Med; 2013 Jun; 54(6):913-21. PubMed ID: 23564760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.
    Jacot W; Mollevi C; Fina F; Lopez-Crapez E; Martin PM; Colombo PE; Bibeau F; Romieu G; Lamy PJ
    BMC Cancer; 2015 Dec; 15():986. PubMed ID: 26680641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular pathways: PI3K pathway targets in triple-negative breast cancers.
    Gordon V; Banerji S
    Clin Cancer Res; 2013 Jul; 19(14):3738-44. PubMed ID: 23748695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Potential role of targeted therapies in the treatment of triple-negative breast cancer.
    Jia LY; Shanmugam MK; Sethi G; Bishayee A
    Anticancer Drugs; 2016 Mar; 27(3):147-55. PubMed ID: 26682525
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutant p53 drives invasion by promoting integrin recycling.
    Muller PA; Caswell PT; Doyle B; Iwanicki MP; Tan EH; Karim S; Lukashchuk N; Gillespie DA; Ludwig RL; Gosselin P; Cromer A; Brugge JS; Sansom OJ; Norman JC; Vousden KH
    Cell; 2009 Dec; 139(7):1327-41. PubMed ID: 20064378
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neurokinin-1 activation affects EGFR related signal transduction in triple negative breast cancer.
    Wang JG; Yu J; Hu JL; Yang WL; Ren H; Ding D; Zhang L; Liu XP
    Cell Signal; 2015 Jul; 27(7):1315-24. PubMed ID: 25817575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
    Linklater ES; Tovar EA; Essenburg CJ; Turner L; Madaj Z; Winn ME; Melnik MK; Korkaya H; Maroun CR; Christensen JG; Steensma MR; Boerner JL; Graveel CR
    Oncotarget; 2016 Oct; 7(43):69903-69915. PubMed ID: 27655711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth hormone-releasing hormone induced transactivation of epidermal growth factor receptor in human triple-negative breast cancer cells.
    Vacas E; Muñoz-Moreno L; Valenzuela PL; Prieto JC; Schally AV; Carmena MJ; Bajo AM
    Peptides; 2016 Dec; 86():153-161. PubMed ID: 27816751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.
    Balanis N; Carlin CR
    Mol Cell Endocrinol; 2017 Aug; 451():24-30. PubMed ID: 28088463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer.
    Dong Y; Li A; Wang J; Weber JD; Michel LS
    Cancer Res; 2010 Jul; 70(13):5465-74. PubMed ID: 20570903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
    Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
    Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.
    Shin SY; Müller AK; Verma N; Lev S; Nguyen LK
    PLoS Comput Biol; 2018 Jun; 14(6):e1006192. PubMed ID: 29920512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
    von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
    Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ki-67 expression is increased in p16-expressing triple-negative breast carcinoma and correlates with p16 only in p53-negative tumors.
    Sugianto J; Sarode V; Peng Y
    Hum Pathol; 2014 Apr; 45(4):802-9. PubMed ID: 24560018
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of PRMT1 in EGFR methylation and signaling in MDA-MB-468 triple-negative breast cancer cells.
    Nakai K; Xia W; Liao HW; Saito M; Hung MC; Yamaguchi H
    Breast Cancer; 2018 Jan; 25(1):74-80. PubMed ID: 28643125
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
    El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
    Mol Carcinog; 2017 May; 56(5):1383-1394. PubMed ID: 27864890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.